Literature DB >> 2645126

Reactive hypoglycemia.

F D Hofeldt1.   

Abstract

Reactive hypoglycemia is a relatively uncommon meal-induced hypoglycemic disorder. Most patients with adrenergic-mediated symptoms have a diagnosis other than reactive hypoglycemia. In many patients with this self-diagnosis, other disorders can be attributed as a cause for symptoms, especially neuropsychiatric disease. The continued use of the terminology "functional hypoglycemia" only contributes vagueness to our correct understanding of this metabolic condition. There are a number of conditions associated with postprandial hypoglycemia. One category is the reactive hypoglycemias, which occur in patients with diabetes mellitus (diabetes reactive hypoglycemia), gastrointestinal dysfunction (alimentary reactive hypoglycemia), hormonal deficiency states (hormonal reactive hypoglycemia), and a large patient group characterized as having idiopathic reactive hypoglycemia. Of these causes the alimentary, hormonal, and diabetic patients are less disputed, whereas the idiopathic reactive hypoglycemic group has been referred to as a "nondisease" group. Characteristic alterations in insulin secretion accompany each of these conditions. In bona fide patients, dysinsulinism or hyperinsulinism usually accounts for the hypoglycemia. Some patients may have increased insulin sensitivity, but this association is doubtful or very rare. Patients with this meal-related eating disorder are characterized as ingesting excessive quantities of refined carbohydrate. In the research setting, the disorder can easily be elicited with the oral glucose tolerance test. However, to establish clinical relevance, the hypoglycemia needs documentation in the home setting with measurements of blood glucose during a postpradial symptomatic episode. The reactive hypoglycemic patients are frequently confused with patients with underlying psychiatric illness. Both syndromes are similar, with adrenergic-mediated symptoms and a common characteristic personality as noted on Minnesota Multiphasic Personality Inventory (MMPI) testing. Patients with bona fide meal-related reactive hypoglycemia should be treated primarily with dietary restriction of refined carbohydrates; other patients may require medications.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2645126

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  7 in total

1.  Persistent vegetative state and the right to die: the United States and Britain.

Authors:  B Jennett; C Dyer
Journal:  BMJ       Date:  1991-05-25

2.  Presence of extrapancreatic islets of Langerhans in the duodenal wall of the rat.

Authors:  M Bendayan; I S Park
Journal:  Diabetologia       Date:  1991-08       Impact factor: 10.122

3.  Nocturnal reactive hypoglycaemia well treated subjectively and objectively with voglibose.

Authors:  Hiroyuki Koyama; Hideomi Ohguchi; Takashi Yagi; Kenro Imaeda
Journal:  BMJ Case Rep       Date:  2017-10-04

Review 4.  Pathologic pancreatic endocrine cell hyperplasia.

Authors:  Debra Ouyang; Deepti Dhall; Run Yu
Journal:  World J Gastroenterol       Date:  2011-01-14       Impact factor: 5.742

5.  Idiopathic reactive hypoglycemia: a role for glucagon?

Authors:  F Leonetti; L Morviducci; A Giaccari; P Sbraccia; S Caiola; D Zorretta; O Lostia; G Tamburrano
Journal:  J Endocrinol Invest       Date:  1992-04       Impact factor: 4.256

6.  Frataxin deficiency in pancreatic islets causes diabetes due to loss of beta cell mass.

Authors:  Michael Ristow; Hindrik Mulder; Doreen Pomplun; Tim J Schulz; Katrin Müller-Schmehl; Anja Krause; Malin Fex; Helene Puccio; Jörg Müller; Frank Isken; Joachim Spranger; Dirk Müller-Wieland; Mark A Magnuson; Matthias Möhlig; Michel Koenig; Andreas F H Pfeiffer
Journal:  J Clin Invest       Date:  2003-08       Impact factor: 14.808

7.  Glucose-responsive Insulinoma with Insulin Hypersecretion Suppressed by Metformin.

Authors:  Kunihisa Hamano; Kayo Akita; Yoko Takeuchi; Tetsuya Suwa; Jun Takeda; Shuji Dodo
Journal:  Intern Med       Date:  2019-08-28       Impact factor: 1.271

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.